The core activity of cellvie is the development of cell-based medicines, in particular by exploiting the therapeutic potential of mitochondria. The company focuses on the development of Therapeutic Mitochondrial Transplantation (TMT), a novel treatment approach aimed at improving cellular energy production and thereby treating various diseases and conditions such as ischemia-reperfusion injury, aging and others.
AI-generated
Offering
Products & services
Industry:
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Therapeutic mitochondria transplantation for augmentation and replacement of mitochondria, to revitalize cellular energy metabolism and treat damaged cells directly.
Treatment of ischemia-reperfusion injuries
Treatment of ischemia-reperfusion injuries, initially in kidney transplantations; with a focus on organ salvage, less delayed graft function, and later expansion to other indications.
Mitochondria-assisted gene therapy for genetic disorders
Topical mitochondria-assisted gene therapy for targeted gene delivery, initially in Epidermolysis bullosa; with restoration of Type VII collagen and expansion to other indications.